Get the Daily Brief
Latest Biotech News
GSK Buys 35Pharma for $950M — Adds HS‑235 Pulmonary Hypertension Asset
GSK agreed to acquire Canadian biotech 35Pharma for $950 million in cash, obtaining HS‑235, a protein‑based candidate targeting the activin receptor signaling pathway for pulmonary arterial...
Astellas and Vir Ink Partnership on Masked PSMA T‑Cell Engager — Deal Tops $1.7B
Astellas and Vir Biotechnology struck a global co‑development and co‑commercialization deal for VIR‑5500, a PRO‑XTEN masked T‑cell engager targeting PSMA in prostate cancer. The agreement could...
FDA Unveils Ultra‑Rare Therapy Framework — Makary Defends Recent Rare‑Drug Rejections
The FDA published a draft framework to expedite therapies tailored to ultra‑rare diseases, outlining a pathway for individualized genome‑editing and RNA‑based treatments when randomized trials are...
Laser Ablation Plus Pembrolizumab Shows Promise in Recurrent High‑Grade Astrocytoma
A Phase 1/randomized Phase 2b study published in Nature Communications reported that combining laser interstitial thermal therapy (LITT) with adjuvant pembrolizumab produced encouraging responses...
Beam Advances BEAM‑304 Base Editing Program for PKU — IND Planned in 2026
Beam Therapeutics announced BEAM‑304, a liver‑targeted base‑editing program to correct pathogenic PAH mutations that cause phenylketonuria (PKU). The company plans to file an IND in 2026 and to...
Protagonist Opts for $400M Cash Over Profit‑Share with Takeda on Rusfertide
Protagonist Therapeutics confirmed it will opt out of a profit‑sharing agreement with Takeda for its hematology asset rusfertide and instead take a one‑time $400 million cash payment. The decision...
Vir, Astellas ink up-to-$1.7B PSMA T‑cell engager pact: Co‑develop and co‑commercialize VIR‑5500
Vir Biotechnology and Astellas agreed to co-develop and co-commercialize VIR-5500, a PRO-XTEN masked T-cell engager targeting prostate-specific membrane antigen (PSMA). The upfront and near-term...
GSK pays $950M for 35Pharma — buys a pulmonary‑hypertension challenger
GSK agreed to acquire 35Pharma for $950 million in cash to gain HS‑235, a protein therapeutic positioned as a 'best‑in‑class' competitor for pulmonary arterial hypertension (PAH). The deal...
FDA backtracks: Immedica’s Loargys accelerated to patients after earlier rejection
The FDA granted accelerated approval to Immedica Pharma’s Loargys (pegzilarginase) for arginase 1 deficiency (ARG1‑D), reversing a 2023 refusal-to-file and clearing an enzyme replacement therapy...
FDA outlines personalized path for ultra‑rare therapies: Plausible mechanism draft guidance
The FDA released a draft framework to expedite therapies for ultra‑rare diseases, focusing on individualized, mechanism‑targeting treatments including genome editing and RNA modalities. The...
Novo picks Vivtex for oral biologics push — potential $2.1B collaboration
Novo Nordisk struck a collaboration with Vivtex to co‑develop oral formulations of peptide and protein therapeutics, a deal valued at up to $2.1 billion including milestones and royalties. The...
Beam expands gene editing and secures strategic license deals — PKU program advances
Beam Therapeutics launched BEAM‑304, a liver‑targeted base‑editing program aimed at correcting common PAH mutations that cause phenylketonuria (PKU), and expects an IND filing in 2026. The company...
Novo cuts GLP‑1 list prices amid competitive pressure and new data
Novo Nordisk announced steep list‑price reductions for its GLP‑1 medicines, lowering monthly list prices to $675 effective 2027 as the company responds to pricing pressure and competitive data...
PacBio and DNAstack launch federated HiFi platform for global rare‑disease genomics
Pacific Biosciences partnered with DNAstack to host a federated environment for sharing HiFi long‑read whole‑genome sequencing data across the HiFi Solves Global Consortium. The platform enables...
Slate Medicines raises $130M to advance anti‑PACAP migraine antibody
Slate Medicines closed a $130 million Series A to develop SLTE‑1009, a monoclonal antibody targeting PACAP for migraine prevention, positioning the company as an alternative to CGRP‑directed...
Ultima Genomics taps Hamilton to automate high‑throughput sequencing workflows
Ultima Genomics and Hamilton announced a collaboration to automate sample‑prep and amplification workflows on Hamilton’s Microlab STAR platform, aiming to scale next‑generation sequencing...
Novo Nordisk doubles down on oral biologics: $2.1B Vivtex pact
Novo Nordisk signed a collaboration with Vivtex to develop oral formulations of peptide and protein therapeutics for obesity, diabetes and related metabolic diseases. The agreement can total up to...
Astellas and Vir team on masked T‑cell engager: up to $1.7B
Astellas Pharma and Vir Biotechnology agreed to co‑develop and co‑commercialize VIR‑5500, a PRO‑XTEN masked CD3 T‑cell engager targeting PSMA, under a deal potentially worth more than $1.7 billion...
GSK pays $950M for 35Pharma – adds PAH candidate HS‑235
GSK agreed to acquire 35Pharma for $950 million in cash to obtain HS‑235, a protein‑based candidate aimed at pulmonary arterial hypertension (PAH). HS‑235 completed a Phase I study and is set to...
Scale breakthrough: 220,000 variants mapped to cell function
Researchers at The Jackson Laboratory, Broad Institute, and Yale executed a massively parallel reporter assay testing over 220,000 single‑nucleotide variants across five human cell types,...